Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GTXI $0.95 0.1300 +15.85%
ONCY $0.46 0.0300 +6.98%
RNN $0.52 0.0244 +4.93%
KERX $3.36 0.1250 +3.87%
CPXX $1.74 0.0150 +0.87%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ADXS $9.43 -1.8000 -16.03%
EPZM $13.09 -1.8800 -12.56%
AGIO $64.12 -8.4300 -11.62%
INCY $107.19 -13.6414 -11.29%
CLDX $10.53 -1.3299 -11.21%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

(Stockhouse) Sept 23, 2015 - Provectus Biopharmaceuticals, Inc. today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.
read article 

Amgen To Present New Kyprolis® (carfilzomib) Data At 15th International Myeloma Workshop

(CNN Money) Sept 23, 2015 - Additional data from phase 3 ASPIRE trial including age analysis and quality of life results.
read article 

Clovis Oncology Announces Data Presentations At 2015 European Cancer Congress

(Clovis Oncology) Sept 23, 2015 - Three oral presentations and four scientific posters selected for presentation at the European Cancer Congress in Vienna, Austria; rucaparib oral presentation on Tuesday, September 29 to include final outcomes data from full ARIEL2 part 1 population of 206 women with advanced ovarian cancer; clinical updates on rociletinib in various patient subsets with advanced disease.
read corporate press release 

Radiation Tx Impact Varies With Comorbidity in Prostate Cancer

(Physician’s Briefing/HealthDay News) Sept 22, 2015 - For men with unfavorable-risk prostate cancer, the impact of radiotherapy (RT) versus RT plus androgen deprivation therapy (ADT) varies with comorbidity, according to a research letter published in the Sept. 22/29 issue of the Journal of the American Medical Association.
read article 

Microbiome Diversity Affects Chemotherapy-Related Infection

(Medscape Medical News) Sept 22, 2015 - The microbiome of patients with acute myelogenous leukemia (AML) has a significant impact on the risk for infectious complication in the first 3 months of induction chemotherapy, results from a new study suggest.
read article (free registration required) 

Maintenance Therapy for Myeloma Evolves

(MedPage Today) Sept 22, 2015 - Early use of maintenance therapy in multiple myeloma and continuous dosing have improved outcomes in patients, but the optimal maintenance strategy remains a work in progress, according to a review of recent data.
read article (free registration required) 

Could Aspirin Treat Breast Cancer?

(Dana-Farber Cancer Institute) Sept 21, 2015 - The first ever randomized trial in the United States testing aspirin in breast cancer, which impacts more than 3 million American women, will test whether it helps women with the disease avoid recurrence and live longer.
read press release 

Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results

(NASDAQ/Dow Jones Business News) Sept 23, 2015 - Amgen Inc. and Allergan PLC said their investigational biosimilar treatment for advanced lung cancer demonstrated clinical equivalence in safety and effectiveness compared with Roche Holding AG’s Avastin.
read article  

OncoGenex's Pancreatic Cancer Drug Found Ineffective In Study

(Reuters) Sept 23, 2015 - Drug developer OncoGenex Pharmaceuticals Inc said its experimental combination therapy for pancreatic cancer was not effective in a mid-stage study.
read article 

OncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic Pancreatic Cancer

(MarketWatch) Sept 23, 2015 - The addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit compared to ABRAXANE and gemcitabine alone.
read article 

Pfizer Says It Could Be Leader in Cancer With Many New Drugs

(ABC News/Associated Press) Sept 22, 2015 - Drug giant Pfizer is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in one of the hottest, and most lucrative, areas of medicine.
read article 

Goldman's Lloyd Blankfein: How to Understand a Lymphoma Diagnosis

(Wall Street Journal) Sept 22, 2015 - The disclosure that Lloyd Blankfein, Goldman Sachs Group Inc.’s chairman and chief executive, was diagnosed with lymphoma shines a light on the most common blood cancer, one that comes in many forms and that generally is either curable or can be successfully treated with chemotherapy.
read article (paid subscription required) 

Most Americans Will Be Misdiagnosed at Least Once

(Scientific American) Sept 22, 2015 - Most people in the U.S. will experience at least one misdiagnosis or delayed diagnosis in their lifetimes, according to a new report from the Institute of Medicine (IOM).
read article 

What's Hot at ECC 2015? Immunotherapy and Rare Cancers

(Medscape Medical News) Sept 22, 2015 - New results with immunotherapy, including long-term efficacy findings, and also clinical benefit in rare cancers, are among the highlights of the forthcoming European Cancer Congress (ECC) 2015, to be held in Vienna from September 25 to 29.
read article (free registration required) 

FDA Awards 18 Grants To Stimulate Product Development For Rare Diseases

( Sept 21, 2015 - The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.
read press release 

Amid Turmoil, Executive Defends Drug Price Hike

(Boston Globe/New York Times) Sept 22, 2015 - A huge overnight price increase for an important tuberculosis drug has been rescinded after the company that acquired the drug gave it back to its previous owner under pressure, it was announced Monday.
read article (free registration required) 

FDA Experts To Review Safety Of Essure Birth Control Implant

(Chicago Tribune/Associated Press) Sept 22, 2015 - Federal medical experts will take a closer look at a host of problems reported with the birth control implant called Essure, including chronic pain, bleeding, headaches and allergic reactions.
read article 

FDA Approves New Oral Medication To Treat Patients With Advanced Colorectal Cancer

( Sept 22, 2015 - The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.
read press release 

Discovery and Human Longevity Aim To Shape Health With Genetics

(Financial Times) Sept 22, 2015 - A partnership between Human Longevity Inc (HLI), a US bioscience company, and Discovery, the South African health insurer, aims to open up a new market for DNA testing and analysis.
read article (free registration required) 

'Breakthrough' Drug May Not Mean What You Think

( Sept 22, 2015 - What the Food and Drug Administration calls a 'breakthrough' drug is often not the same as what a layperson would call a breakthrough, a new study shows.
read article 

Goldman Chief Lloyd Blankfein Discloses 'Highly Curable’ Cancer

(Forbes) Sept 22, 2015 - In a memo sent to employees and filed on the SEC’s website, Goldman Sachs chairman and CEO Lloyd Blankfein revealed Tuesday morning that he has a “highly curable” form of lymphoma.
read article 

It Is Time For An Honest Conversation About Money And Cancer

(KevinMD blog) Sept 22, 2015 - There are two, old, particularly nasty rumors, about cash and cancer.
read article 

National Cancer Experience Survey Gives Voice to Patients and Caregivers

(CTCA) Sept 17, 2015 - Insights reveal gaps in cancer care, underscore need for more coordinated care models.
read press release 

Susan G. Komen® 2015 Breast Cancer Research Funding Targets Early-Career Investigators, New Therapies, Health Inequities, and Metastatic Disease

(Susan G. Komen) Sept 22, 2015 - Susan G. Komen, the world’s largest nonprofit funder of breast cancer research, announced new grants to 124 researchers in 25 states and eight countries internationally, with about half of the grants targeted to early-career researchers squeezed by stagnation in federal research dollars.
read press release 

NCI Fields 'Dream Team' for New Pathway-Focused SPORE

(MedPage Today/The Gupta Guide) Sept 21, 2015 - The National Cancer Institute may be taking a page from Stand Up To Cancer's playbook by funding what is tantamount to a Specialized Programs of Research Excellence (SPORE) "dream team.”
read article (free registration required)